Fig. 4
From: Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
Pathway mutation differential and profile analysis in groups with high or nonhigh PD-L1 expression. Differential analysis of the PI3K signaling pathway (A); The mutation profile of the PI3K signaling pathway in the group with EGFR E19del/L858R mutation and high ( TPS ≥ 50%) or nonhigh (TPS < 50%) PD-L1 expression levels (B). “*” and “***” indicate P < 0.05 and P < 0.001, respectively. Wilcox test